Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Existe información en español para pacientes y cuidadores, para acceder, haga clic sobre “Select” al lado de “I am a U.S. Patient / Caregiver”.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

paricalcitol injection Drug Interactions

7 DRUG INTERACTIONS

Table 4 includes clinically significant drug interactions with Paricalcitol Injection.

Table 4. Clinically Significant Drug Interactions with Paricalcitol Injection
Drugs that May Increase the Risk of Hypercalcemia
Clinical ImpactConcomitant administration of high doses of calcium-containing preparations or other vitamin D compounds may increase the risk of hypercalcemia. Thiazide diuretics are known to induce hypercalcemia by reducing excretion of calcium in the urine.
ExamplesCalcium-containing products, other vitamin D compounds or thiazide diuretics
InterventionMonitor calcium more frequently and adjust Paricalcitol Injection dose as needed [see Warnings and Precautions (5.1)].
Digitalis Compounds
Clinical ImpactParicalcitol Injection can cause hypercalcemia which can potentiate the risk of digitalis toxicity.
InterventionMonitor patients for signs and symptoms of digitalis toxicity and increase frequency of serum calcium monitoring when initiating or adjusting the dose of Paricalcitol Injection in patients receiving digitalis compounds [see Warnings and Precautions (5.2)].
Strong CYP3A Inhibitors
Clinical ImpactParicalcitol Injection is partially metabolized by CYP3A. Exposure of Paricalcitol Injection will increase upon coadministration with strong CYP3A inhibitors [see Clinical Pharmacology (12.3)].
ExamplesClarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, and voriconazole
InterventionIf a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor, dose adjustment of Paricalcitol Injection may be necessary. Monitor intact PTH and serum calcium concentrations closely.
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event